Highest-materiality recent filing
Lyra Therapeutics terminates Waltham sublease; pays $2.1M termination fee
Termination of sublease for 23,704 sq ft at 880 Winter Street, Waltham, MA, effective March 31, 2026.
Lyra Therapeutics terminates two leases, forfeits $1.4M deposits and pays $2.5M in fees
Watertown lease (22,343 SF): forfeits $302,514.84 LC deposit + pays $1M modification; lease ends May 31, 2026.
Lyra Therapeutics to suspend trading on Nasdaq March 17 after delisting appeal withdrawal
Company withdrew appeal of February 2, 2026 Nasdaq delisting determination.
Lyra Therapeutics receives default notice for $484K unpaid rent; wind-down continues
Received default notice from sublessor RVAC on Feb 23, 2026 for unpaid rent at Waltham office.
Nasdaq notifies Lyra Therapeutics of delisting; company deemed a public shell
Nasdaq cites public shell status after suspension of lead drug LYR-210 and near-complete workforce reduction.
Lyra suspends LYR-210 development, lays off nearly all staff; CEO/CFO become consultants
Board approved plan to suspend LYR-210 development and reduce workforce affecting substantially all employees, effective Jan 12, 2026.
Lyra Therapeutics reports Q3 net loss $6.0M, plans new Phase 3 trial for LYR-210
Cash and cash equivalents $22.1M at Sep 30, 2025; cash runway into Q3 2026.
Lyra Therapeutics receives Nasdaq deficiency notice for equity below $2.5M minimum
Stockholders' equity as of June 30, 2025 was ~$1.6M, below the $2.5M continued listing requirement.
Lyra Therapeutics Q2 2025 net loss $7.4M; cash $29.8M; ENLIGHTEN 2 Phase 3 met primary endpoint
Net loss Q2 2025 $7.4M vs $48.1M YoY due to lower R&D and no impairment charges.
Lyra Therapeutics raises $5M upfront (up to $15M with warrant exercise) in equity offering
Upfront gross proceeds of $5.0M from sale of 423,372 shares (or pre-funded warrants) at $11.81 per share+private warrant.
ENLIGHTEN 2 met primary endpoint: LYR-210 improved 3CS composite score vs sham at 24 weeks (-1.13, p=0.0078) in non-polyp patients.
Lyra Therapeutics approves 1-for-50 reverse stock split, effective May 27
Stockholders approved reverse-split authority at 1-for-10 to 1-for-50 range; Board set final ratio at 1-for-50.
Lyra Therapeutics reports Q1 net loss of $8.5M; ENLIGHTEN 2 top-line results expected Q2 2025
Net loss of $8.5M ($0.13 per share) vs. $22.5M ($0.35) in Q1 2024; cash burn reduced YoY.
Lyra Therapeutics reports FY2024 net loss $93.4M; ENLIGHTEN 2 top-line data expected Q2 2025
Net loss for FY2024 was $93.4M ($1.43 diluted EPS) vs $62.7M in FY2023; cash $40.6M as of Dec 31, 2024.
Lyra Therapeutics Q2 net loss $48.1M; workforce cut 75%; ENLIGHTEN 1 subgroup positive
Q2 net loss $48.1M vs $15.6M YoY, including $22.8M right-of-use asset impairment and $6.5M restructuring charge.
Nasdaq notified Lyra on July 19, 2024 that its common stock (LYRA) closed below $1.00 for 30 consecutive business days.
Lyra Therapeutics estimates $3.9-4.1M in charges from workforce reduction of up to 87 employees
Board approved workforce reduction of up to 87 employees, effective May 21 and June 20, 2024.
Lyra Therapeutics cuts workforce by up to 87 employees, CTO departing in restructuring
Board approved reduction of up to 87 employees, ~80 effective May 21 and ~7 effective June 20, 2024.
Lyra Therapeutics Q1 net loss $22.5M; ENLIGHTEN 1 Phase 3 results expected in May 2024
Cash $87.1M at March 31, 2024 vs $102.8M at Dec 31, 2023; cash runway into Q1 2025.
Lyra reports BEACON Phase 2 smell-loss data: 0.87 improvement at week 24 (p=0.026)
BEACON Phase 2 trial: 0.87 improvement in smell loss vs control at week 24 (p=0.026) in patients with impaired smell at baseline.
Lyra reports Q3 net loss $15.7M; Phase 2 CT data shows objective improvement in CRS
CT data for LYR-220: ethmoid sinus opacification improved vs sham (p=0.035) at 24 weeks.
Lyra Therapeutics Q2 net loss $15.6M; cash $116.2M after $46.7M placement
Cash and investments $116.2M at June 30, 2023, up from $82.7M at March 31, 2023.
Lyra Therapeutics announces $50M private placement; extends cash runway into Q1 2025
Gross proceeds of ~$50M from sale of ~17.7M shares, ~2.4M pre-funded warrants, and ~10.0M purchase warrants at $2.4925 per unit.
Net loss for FY2022 $55.3M vs $43.5M in 2021; Q4 net loss $14.2M.
Lyra Therapeutics Q3 net loss $14.8M; pauses ENLIGHTEN II enrollment for in-house mfg
Net loss of $14.8M for Q3 2022, compared to $11.1M in Q3 2021.
Lyra Therapeutics restates Q1/Q2 2022 financials due to $5M milestone error
Audit Committee concludes Q1 and Q2 2022 financials no longer reliable due to $5.0M milestone revenue recognition error from LianBio agreement.
Lyra presents additional Phase 2 LANTERN data for LYR-210 at ARS meeting
Posted slide presentation with additional Phase 2 results from LANTERN trial of LYR-210 for chronic rhinosinusitis.
Lyra Therapeutics Q1 2022 net loss of $7.0M; secures $100.5M private placement
Net loss for Q1 2022 was $7.0M, compared to $7.8M in Q1 2021.
On April 15, 2024, Edward T. Anderson resigned from the Board of Directors (the “ Board ”) of Lyra Therapeutics, Inc. (the “ Company ”) as well as the Audit Committee and Compensation Committee of the Board.
On February 16, 2022, the Board of Directors of Lyra Therapeutics, Inc. (the “Company”) appointed Harlan Waksal, M.D. as a Class II director of the Company and Chairperson of the Board, and as the Executive Chair and an executive officer of the Company.
Mr. Cavalier was also designated as the Company’s principal financial officer and principal accounting officer, and succeeds R. Don Elsey as Chief Financial Officer and principal financial officer and principal accounting officer.
On September 12, 2021, the Board of Directors (the “Board”) of Lyra Therapeutics, Inc. (the “Company”) appointed Jason Cavalier as Chief Financial Officer, Treasurer and Secretary of the Company.
Max materiality 0.95 · Median 0.60 · Most common event other_material